These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20164833)

  • 21. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.
    Xiong W; Candolfi M; Kroeger KM; Puntel M; Mondkar S; Larocque D; Liu C; Curtin JF; Palmer D; Ng P; Lowenstein PR; Castro MG
    Mol Ther; 2008 Feb; 16(2):343-51. PubMed ID: 18180781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
    Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
    Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AG; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-690. PubMed ID: 28178463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
    Mineharu Y; Kamran N; Lowenstein PR; Castro MG
    Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
    Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.
    Xiong W; Goverdhana S; Sciascia SA; Candolfi M; Zirger JM; Barcia C; Curtin JF; King GD; Jaita G; Liu C; Kroeger K; Agadjanian H; Medina-Kauwe L; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2006 Jan; 80(1):27-37. PubMed ID: 16352528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
    Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
    Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy for brain tumors: basic developments and clinical implementation.
    Assi H; Candolfi M; Baker G; Mineharu Y; Lowenstein PR; Castro MG
    Neurosci Lett; 2012 Oct; 527(2):71-7. PubMed ID: 22906921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
    Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
    Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
    Xiong W; Candolfi M; Liu C; Muhammad AK; Yagiz K; Puntel M; Moore PF; Avalos J; Young JD; Khan D; Donelson R; Pluhar GE; Ohlfest JR; Wawrowsky K; Lowenstein PR; Castro MG
    PLoS One; 2010 Jun; 5(6):e11074. PubMed ID: 20552015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors.
    Thomas CE; Schiedner G; Kochanek S; Castro MG; Lowenstein PR
    Hum Gene Ther; 2001 May; 12(7):839-46. PubMed ID: 11339900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
    Candolfi M; Xiong W; Yagiz K; Liu C; Muhammad AK; Puntel M; Foulad D; Zadmehr A; Ahlzadeh GE; Kroeger KM; Tesarfreund M; Lee S; Debinski W; Sareen D; Svendsen CN; Rodriguez R; Lowenstein PR; Castro MG
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20021-6. PubMed ID: 21030678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
    Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
    Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
    Kuriyama N; Kuriyama H; Julin CM; Lamborn KR; Israel MA
    Cancer Res; 2001 Mar; 61(5):1805-9. PubMed ID: 11280727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.
    Puntel M; Curtin JF; Zirger JM; Muhammad AK; Xiong W; Liu C; Hu J; Kroeger KM; Czer P; Sciascia S; Mondkar S; Lowenstein PR; Castro MG
    Hum Gene Ther; 2006 May; 17(5):531-44. PubMed ID: 16716110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gene therapy of cerebral glioblastoma by adenovirus vector. Experimental model in the rat].
    Dufour T; Quillien V; Heresbach N; Denais A; Ferry N; Guegan Y
    Chirurgie; 1998 Apr; 123(2):168-74. PubMed ID: 9752539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
    Hoffmann D; Wildner O
    Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies.
    Vincent AJ; Esandi MC; Avezaat CJ; Vecht CJ; Sillevis Smitt P; van Bekkum DW; Valerio D; Hoogerbrugge PM; Bout A
    Neurosurgery; 1997 Aug; 41(2):442-51; discussion 451-2. PubMed ID: 9257313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.